Intellia Therapeutics, Inc. is an American biotechnology company specializing in gene editing for therapeutic purposes. Based in Cambridge, Massachusetts, it seeks to turn DNA modification tools into medicines. Its approach notably involves delivering these tools into the body to act on targeted cells, rather than regularly administering a treatment intended to compensate for the consequences of a disease.
A biotech company born of the CRISPR revolution
Founded in 2014, Intellia belongs to the generation of companies created to harness the therapeutic potential of CRISPR-Cas9. This technology combines a guide RNA, which recognizes a genetic sequence, with an enzyme capable of cutting DNA. The cell’s repair mechanisms can then be harnessed to modify how a gene functions.
Listed on Nasdaq in 2016 under the ticker symbol NTLA, the company has built its development around clinical research and industry collaborations, notably with Regeneron. In 2021, published clinical results from its transthyretin amyloidosis program documented the possibility of editing a gene directly inside the human body through systemic administration.
Treatments designed to act at the source
One of its main areas of focus is transthyretin amyloidosis, a disease in which a protein can form deposits that cause cardiac or neurological damage. Developed with Regeneron, the candidate NTLA-2001 aims to inactivate the TTR gene in liver cells to reduce production of this protein. In 2024, the program entered phase III for the form of the disease that affects the heart.
Intellia is also developing NTLA-2002 for hereditary angioedema, which is characterized by potentially severe swelling attacks. This candidate targets the KLKB1 gene, involved in the production of prekallikrein, to intervene in a biological pathway that causes the attacks. In both programs, the ambition is to produce a prolonged effect through a genetic modification carried out during a single administration.
This strategy relies on lipid nanoparticles that carry the components needed for editing to liver cells. It draws on expertise in molecular biology, formulation, pharmaceutical manufacturing and clinical development. Editing precision, its distribution within the body and the monitoring of adverse effects are issues just as important as the intended efficacy.
What next?
Intellia’s trajectory will depend on its trials’ ability to demonstrate a lasting clinical benefit beyond a reduction in a biological marker. For interventions designed to make lasting changes to DNA, long-term follow-up and assessment of the benefit-risk balance are crucial. Industrial-scale manufacturing, regulatory requirements and conditions for access to treatments will also influence their potential adoption. The challenge is therefore to turn proof of mechanism into a reproducible, safe therapeutic solution that is relevant compared with already available options.